Pancreatic cancer: Progress made

Vlad V. Simianu, Nicholas J. Zyromski, Attila Nakeeb, Keith D. Lillemoe

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Pancreatic cancer remains a deadly disease. Despite advances on many fronts, surgeons play a leading role in the diagnosis and management of pancreatic cancer. Preoperative staging is best provided by "pancreas- protocol" abdominal CT, although endoscopic ultrasound and diagnostic laparoscopy can add value in selected patients. Surgical resection, which remains the only curative option, is now accomplished with uniformly low perioperative mortality in high-volume centers (<3%), although complications remain frequent. Unfortunately, the long-term prognosis for pancreatic cancer remains poor with 5-year survival rates only 15-23% with median survival of 13 to 18 months. Recent data from randomized trials have supported the role for adjuvant chemotherapy and questioned the traditional role of radiation. Early diagnosis and targeted multimodality treatments would appear essential to optimizing the results of surgical therapy.

Original languageEnglish (US)
Pages (from-to)407-417
Number of pages11
JournalActa Oncologica
Volume49
Issue number4
DOIs
StatePublished - Apr 28 2010

Fingerprint

Pancreatic Neoplasms
Adjuvant Chemotherapy
Laparoscopy
Early Diagnosis
Pancreas
Ultrasonography
Survival Rate
Radiation
Survival
Mortality
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Pancreatic cancer : Progress made. / Simianu, Vlad V.; Zyromski, Nicholas J.; Nakeeb, Attila; Lillemoe, Keith D.

In: Acta Oncologica, Vol. 49, No. 4, 28.04.2010, p. 407-417.

Research output: Contribution to journalArticle

Simianu, Vlad V. ; Zyromski, Nicholas J. ; Nakeeb, Attila ; Lillemoe, Keith D. / Pancreatic cancer : Progress made. In: Acta Oncologica. 2010 ; Vol. 49, No. 4. pp. 407-417.
@article{8f9e29944aff402b8897877ed065e77a,
title = "Pancreatic cancer: Progress made",
abstract = "Pancreatic cancer remains a deadly disease. Despite advances on many fronts, surgeons play a leading role in the diagnosis and management of pancreatic cancer. Preoperative staging is best provided by {"}pancreas- protocol{"} abdominal CT, although endoscopic ultrasound and diagnostic laparoscopy can add value in selected patients. Surgical resection, which remains the only curative option, is now accomplished with uniformly low perioperative mortality in high-volume centers (<3{\%}), although complications remain frequent. Unfortunately, the long-term prognosis for pancreatic cancer remains poor with 5-year survival rates only 15-23{\%} with median survival of 13 to 18 months. Recent data from randomized trials have supported the role for adjuvant chemotherapy and questioned the traditional role of radiation. Early diagnosis and targeted multimodality treatments would appear essential to optimizing the results of surgical therapy.",
author = "Simianu, {Vlad V.} and Zyromski, {Nicholas J.} and Attila Nakeeb and Lillemoe, {Keith D.}",
year = "2010",
month = "4",
day = "28",
doi = "10.3109/02841860903447051",
language = "English (US)",
volume = "49",
pages = "407--417",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Pancreatic cancer

T2 - Progress made

AU - Simianu, Vlad V.

AU - Zyromski, Nicholas J.

AU - Nakeeb, Attila

AU - Lillemoe, Keith D.

PY - 2010/4/28

Y1 - 2010/4/28

N2 - Pancreatic cancer remains a deadly disease. Despite advances on many fronts, surgeons play a leading role in the diagnosis and management of pancreatic cancer. Preoperative staging is best provided by "pancreas- protocol" abdominal CT, although endoscopic ultrasound and diagnostic laparoscopy can add value in selected patients. Surgical resection, which remains the only curative option, is now accomplished with uniformly low perioperative mortality in high-volume centers (<3%), although complications remain frequent. Unfortunately, the long-term prognosis for pancreatic cancer remains poor with 5-year survival rates only 15-23% with median survival of 13 to 18 months. Recent data from randomized trials have supported the role for adjuvant chemotherapy and questioned the traditional role of radiation. Early diagnosis and targeted multimodality treatments would appear essential to optimizing the results of surgical therapy.

AB - Pancreatic cancer remains a deadly disease. Despite advances on many fronts, surgeons play a leading role in the diagnosis and management of pancreatic cancer. Preoperative staging is best provided by "pancreas- protocol" abdominal CT, although endoscopic ultrasound and diagnostic laparoscopy can add value in selected patients. Surgical resection, which remains the only curative option, is now accomplished with uniformly low perioperative mortality in high-volume centers (<3%), although complications remain frequent. Unfortunately, the long-term prognosis for pancreatic cancer remains poor with 5-year survival rates only 15-23% with median survival of 13 to 18 months. Recent data from randomized trials have supported the role for adjuvant chemotherapy and questioned the traditional role of radiation. Early diagnosis and targeted multimodality treatments would appear essential to optimizing the results of surgical therapy.

UR - http://www.scopus.com/inward/record.url?scp=77951248404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951248404&partnerID=8YFLogxK

U2 - 10.3109/02841860903447051

DO - 10.3109/02841860903447051

M3 - Article

C2 - 20059311

AN - SCOPUS:77951248404

VL - 49

SP - 407

EP - 417

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 4

ER -